Szeliga Anna, Podfigurna Agnieszka, Meczekalski Blazej
Department of Gynecological Endocrinology, Poznan University of Medical Sciences, Poznan, Poland.
Gynecol Endocrinol. 2022 Nov;38(11):992-996. doi: 10.1080/09513590.2022.2126455. Epub 2022 Sep 23.
Nesfatin-1 plays an important role in regulating metabolism, appetite, gut motility, and eating behavior. It is suspected that abnormalities in nesfatin-1 secretion may be involved in the development of anorexia nervosa, and as such, this study aims to investigate the "circumstances of" nesfatin-1 in patients with functional hypothalamic amenorrhea (FHA).
One hundred and forty-seven patients with FHA were enrolled to the present study. A control group consisting of 88 healthy, age-matched subjects was used. Both study and control groups had blood samples drawn to establish baseline serum concentrations of luteinizing hormone, follicle-stimulating hormone, estradiol, prolactin, thyroid-stimulating hormone, fT4, morning cortisol, dehydroepiandrosterone sulfate, testosterone, glucose, and insulin. Nesfatin-1 was also measured with the use of enzyme-linked immunosorbent assay.
Patients with FHA were found to have a significantly decreased concentration of serum nesfatin-1 when compared to healthy controls (6.21 ± 4.79 vs. 8.64 ± 6.63 respectively, = 0.005). No statistically significant difference in nesfatin-1 levels was found between patients with normal and decreased BMI in the FHA group. Significant positive correlation was observed between serum nesfatin-1 concentration and 17-β-estradiol, while a significant negative correlation was observed between serum nesfatin-1 concentration and patient age, fasting glucose, and HDL levels.
This is the first known study to examine nesfatin-1 concentration in the context of clinical FHA. Patients with FHA were found to have decreased serum nesfatin-1 concentrations. This finding may prove instrumental in our future approach managing patients with FHA.
Nesfatin-1在调节新陈代谢、食欲、肠道蠕动和进食行为方面发挥着重要作用。人们怀疑Nesfatin-1分泌异常可能与神经性厌食症的发病有关，因此，本研究旨在调查功能性下丘脑性闭经（FHA）患者体内Nesfatin-1的“情况”。
147例FHA患者纳入本研究。使用由88名年龄匹配的健康受试者组成的对照组。研究组和对照组均采集血样，以确定黄体生成素、卵泡刺激素、雌二醇、催乳素、促甲状腺激素、游离甲状腺素、晨皮质醇、硫酸脱氢表雄酮、睾酮、葡萄糖和胰岛素的基线血清浓度。Nesfatin-1也采用酶联免疫吸附测定法进行检测。
与健康对照组相比，FHA患者血清Nesfatin-1浓度显著降低（分别为6.21±4.79和8.64±6.63，P = 0.005）。FHA组中BMI正常和降低的患者之间Nesfatin-1水平无统计学显著差异。血清Nesfatin-1浓度与17-β-雌二醇之间存在显著正相关，而血清Nesfatin-1浓度与患者年龄、空腹血糖和高密度脂蛋白水平之间存在显著负相关。
这是已知的第一项在临床FHA背景下检测Nesfatin-1浓度的研究。发现FHA患者血清Nesfatin-1浓度降低。这一发现可能对我们未来治疗FHA患者的方法有帮助。
